1 Avenue de Lafayette,

Boston,

MA,

USA,

ZIP: 02111

Phone: +1 617 455 4188

Returning to Boston in February 2020 is the 8th Neurodegenerative Drug Development Summit, previously World CNS.

Despite the lack of clinical trial success, new investments are being made in forward-thinking biotechs, digital and blood-based biomarker technologies are advancing, new targets are emerging, and gene therapy is taking the limelight.

The Neurodegenerative Drug Development Summit will unite industry stakeholders to learn how to overcome their translational challenges, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics.

Don’t miss your opportunity to join over 150 fellow CNS experts from Biogen, AbbVie, Sanofi and more, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.

URLs:
Tickets: https://go.evvnt.com/552917-1?pid=1052
Brochure: https://go.evvnt.com/552917-3?pid=1052
Booking: https://go.evvnt.com/552917-4?pid=1052
Inquiries: https://go.evvnt.com/552917-5?pid=1052

Prices:
Conference + 3 Workshops: USD 4496.0,
Conference + 2 Workshops: USD 4097.0,
Conference + 1 Workshop: USD 3598.0,
Conference Only: USD 2999.0

Larry Brown, Executive Vice President and Chief Scientific Officer, Noveome Biotherapeutics, Inc., Alison Mungenast, Principal Scientist and Neuroscience Lead, Eisai, Amy Easton, Senior Scientific Manager, Drug Discovery, Genentech, Aparna Vasanthakumar, Principal Research Scientist, Pharmacogenetics and Pharmacogenomics, Genomics Research Center/Chair of PPSP, AbbVie/ADNI, Bob Switzer, Founder, President and Chief Scientific Officer Neuroscience, Associates, Christian Schubert, Global Head, External Innovation, Servier, David Donabedian, Chief Executive Officer, Axial Therapeutics, Eric Schaeffer, Senior Director, Neuroscience Innovation, Janssen, Henrik Zetterberg, Professor, University of Gothenburg, Ilaria Tassi, Lead Scientist, Alector, Ivana Rubino, Global Head of Medical Alzheimer’s, Biogen, James Gorman, Brain Targeting Program, Wyss Institute for Biologically Inspired Engineering, Harvard, Johan Luthman, Executive Vice President and Head of Research and Development, Lundbeck, John Renger, Chief Scientific Officer, Cerevel Therapeutics, Jonathan Brotchie, Co-Founder, Director and President, Atuka Inc, Krystof Bankiewicz, President and CEO, Brain Neurotherapy Bio, Inc., Lamya Shihabuddin, Head of Genetic Neurologic Diseases, Sanofi, Laszlo Kiss, Executive Director, WRD and Principal, Pfizer Ventures, Leslie Shinobu, Senior Director, Clinical Development, Biogen, Michael Gold, Vice President, Neuroscience Development, AbbVie, Nahome Fisseha, Assistant Scientific Director, Neuroscience Clinical Development, AbbVie, Olivier Danos, Chief Scientific Officer, REGENXBIO, Pascal Sanchez, Director, Translational Sciences, Denali Therapeutics, Richard Hargreaves, Vice President, Head Neuroscience and Imaging Research and Early Development, Celgene, Richard Ransohoff, Venture Partner, Third Rock Ventures, Ross Jeggo, Head of Neuroscience Research, Servier, Samantha Hutten, Senior Associate Director, Research Partnerships, Michael J Fox, Sheraz Khan, Director of the Khan Lab, Harvard, MGH and MIT, Sid O’Bryant, Executive Director, Institute for Translational Research; Professor, Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Sophie Parmentier Batteur, Director, Neuroscience Discovery, Merck, Will Chen, Senior Director, Translational Biology, Biogen, Yaming Wang, Senior Research Scientist, Eli Lilly